SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris NASDAQ:PHVS, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) an…

PHVS

Related stories